Correspondence 0001437749-24-003658 from Moleculin Biotech, Inc. (MBRX)
Moleculin Biotech, Inc.
Date: Feb. 9, 2024 · CIK: 0001659617 · Accession: 0001437749-24-003658
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276851
Letter
Re:
mbrx20240209_corresp.htm
February 9, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporate Finance
Washington, DC 20549
Attention: Chris Edwards
Moleculin Biotech, Inc.
Registration Statement on Form S-1
Registration No. 333-276851
Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, as amended, Moleculin Biotech, Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:30 P.M. (Eastern Time) on February 12, 2024, or as soon thereafter as possible on such date.
Very truly yours,
Moleculin Biotech, Inc.
Show Raw Text
CORRESP 1 filename1.htm mbrx20240209_corresp.htm February 9, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Attention: Chris Edwards Re: Moleculin Biotech, Inc. Registration Statement on Form S-1 Registration No. 333-276851 Ladies and Gentlemen: Pursuant to Rule 461 of the Securities Act of 1933, as amended, Moleculin Biotech, Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:30 P.M. (Eastern Time) on February 12, 2024, or as soon thereafter as possible on such date. Very truly yours, Moleculin Biotech, Inc. By: /s/ Jonathan Foster Name: Jonathan Foster Title: Chief Financial Officer